Breaking
Notable MedicineSTAT (INT)

STAT+: Expert warns of battleground over global access to newer GLP-1 drugs for obesity

Over the past few months, lower-cost generic versions of the blockbuster GLP-1 drug semaglutide, which is sold as Wegovy by Novo Nordisk for combating obesity, started to become available in some countries and will soon arrive in still others…

Read the full story at STAT ↗

ImpactNotable
Published5 h ago (Mon, 16 Nov 2026 18:18:25 GMT)
AuthorEd Silverman
MoreLess
Impact score33/100
RatingProbability of 68%.
RegionsGlobal
Retrievedvia rss
ClassifiedMon, 16 Nov 2026 19:01:24 GMT by classifier